secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2023-07-28T23:59:59+00:00
Accession:  0001104659-23-085398
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 1.01, 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRX Pharmaceuticals amends Streeterville note; receives Nasdaq MVLS delisting notice
--------------------------------------------------------------------------------

- Amendment #2 to $11.02M convertible note: $1.8M cash paid July 10, then $400K/month through Dec 2023, payable in cash or shares.
- Company may pay redemption amounts in common stock even if Equity Conditions Failure exists; Streeterville waived prior defaults.
- Nasdaq notified NRXP on July 20 that MVLS fell below $50M; 180-day cure period until Jan 22, 2024, for continued listing.
- Redemption Premium continues on all payments; shareholder dilution possible from share conversions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000110465923085398/0001104659-23-085398-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000110465923085398/tm2317653d9_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-085398

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer